Lee H J, Nathoo Z M
Steroids. 1983 May;41(5):609-15. doi: 10.1016/0039-128x(83)90026-0.
The systemic activities of methyl 20-dihydroprednisolonate (1), a new local anti-inflammatory steroid synthesized by modifying the 17 beta-ketol side-chain of prednisolone, on pituitary-adrenal function and liver glycogen content were investigated in rats. The parent compound, prednisolone, administered intramuscularly, caused a significant dose-related decrease in plasma levels of corticosterone, adrenocorticotropic hormone (ACTH), and liver glycogen content in rats. In contrast, methyl 20-dihydroprednisolonate caused mild PA suppression and liver glycogen depletion only at high doses. The steroid acid ester did not exert glycogenic activity, unlike prednisolone, in the adrenalectomized rats.
通过修饰泼尼松龙的17β - 酮醇侧链合成的新型局部抗炎甾体20 - 二氢泼尼松龙甲酯（1）对大鼠垂体 - 肾上腺功能和肝糖原含量的全身活性进行了研究。母化合物泼尼松龙经肌肉注射给药后，大鼠血浆皮质酮、促肾上腺皮质激素（ACTH）水平及肝糖原含量均出现显著的剂量相关下降。相比之下，20 - 二氢泼尼松龙甲酯仅在高剂量时才引起轻度的垂体 - 肾上腺抑制和肝糖原消耗。与泼尼松龙不同，该甾体酸酯在肾上腺切除的大鼠中不具有糖原生成活性。
